Figure S8 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
Key Points
Key points are not available for this paper at this time.
Abstract
Figure S8 shows the studies with SpiD3AP in CLL.
Eiken et al. (Wed,) studied this question.
Figure S6 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects2024